Human Gene Therapy is the premier, multidisciplinary journal covering all aspects of gene therapy. The Journal is divided into three parts. Human Gene Therapy, the flagship published 12 times per year, HGT Methods, a bimonthly journal, focused on the applications of gene therapy to product testing and development, and HGT Clinical Development, a quarterly journal, publishing data relevant to the regulatory review and commercial development of cell and gene therapy products. This unique three part program provides 22 issues of essential research, technologies, translation, and applications to promote the development of gene therapy products into effective therapeutics for treating human disease—and move this revolutionary field forward.
The Journal is led by a world-renowned Editorial Board with Editor-in-Chief Terence R. Flotte, MD, at the helm; Deputy Editor Europe Thierry VandenDriessche, PhD; Deputy Editor U.S. Barry J. Byrne, MD, PhD; Human Gene Therapy Editor Guangping Gao, PhD; Methods Editor Hildegard Büning, PhD; and Clinical Development Editor James M. Wilson, MD, PhD.
Human Gene Therapy is the Official Journal of 9 international societies, including ESGCT.
During the last congresses and events, the ESGCT has been gathering feedback on the collaboration with Human Gene Therapy, which to date has meant online access to HGT jourmal for active members. In line with changing requirements, the ESGCT is pleased to announce that, effective immeediately, any ESGCT member in good standing (current paid members and students) will receive a 25% discount off Open Access fees, as well as a 25% discount off Page Charges and Color Art fees for all Mary Ann Liebert journals, not just Human Gene Therapy.
Please see below for guidance from the publishers:
Authors must provide their ESGCT membership number on upon return of the Page Charge Billing Form and/or Liebert Open Option Form to receive discounts. Human Gene Therapy, the official journal of ESGCT, welcomes your manuscript submissions and encourages all members to submit! All papers will receive rapid, high-quality peer-review. Accepted papers are published online-ahead-of-print. ESGCT members are also encouraged to recommend the expanded Human Gene Therapy program to their library or institution to facilitate collaboration with colleagues.
Latest Impact Factor: 3.755
2014 Journal Citation Reports® published by Thomson Reuters, 2015